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pyroglutamate derivatives containing 4-hydroxybenzyl units at the N atom and 47 are the ﬁrst
examples of natural products with the 4-hydroxybenzyl unit linked via a thioether bond to 2-hydroxy-3-
mercaptopropanoic acid (46) and 2-hydroxy-4-mercaptobutanoic acid (7), which would be biogeneti-
cally derived from cysteine and homocysteine, respectively. The structures of 1 and 2 were veriﬁed by
synthesis, while the absolute conﬁgurations of 4, 5 and 7 were assigned using Mosher’s method based on
the MPA determination rule of ΔδRS values. The known compound 4-(hydroxymethyl)-5-nitrobenzene-
1,2-diol (8) exhibited activity against Fe2þ-cysteine induced rat liver microsomal lipid peroxidation with
IC50 values of 9.99 106 mol/L.
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Substituted amino acid derivatives from Gastrodia elata 3511. Introduction
Gastrodia elata Blume is a holomycotrophic perennial plant of
the Orchidaceae family, and is widely cultivated in several
provinces of China to meet the demands of pharmaceutical and
food industries1. The steamed and dried rhizome of G. elata,
known as “Tianma” in Chinese, is used for the treatment of
neuralgic and nervous disorders, such as headaches, migraine,
dizziness, tetanus, epilepsy, neuralgia and paralysis. It is also
considered to have health beneﬁts enhancing strength and
virility and improving memory and blood circulation2. Chemi-
cal and pharmacological studies indicated that 4-hydroxybenzyl
analogs and 4-hydroxybenzyl-substituted metabolites were
main active constituents of ethanol or methanol extracts of this
medicine3–8. As part of a program to assess the chemical and
biological diversity of traditional Chinese medicines9–16, a
detailed chemical study was conducted on the aqueous extract
of G. elata rhizomes, together with biological assays, since their
decoctions are practically used in a variety of formulations. A
fraction mainly contained parishin and parishins B and C (total
content 450%), and at dosages of 10.000.25 mg/kg, the
puriﬁed parishins improved the impaired memory in mice
caused by scopolamine or cycloheximide17. In addition, 23
known compounds were characterized from the extract18, and a
minor component N6-(4-hydroxybenzyl)-adenosine (NHBA)19
was isolated as the key sedative and hypnotic constituent of the
extract, exhibiting signiﬁcant activity at a dosage of 0.2 mg/kg
(i.p.)20. Therefore, we carried out further investigation on other
minor components in the extract. This has resulted in isolation
and characterization of seven new 4-hydroxybenzyl-substituted
amino acid derivatives 17 (Fig. 1), along with 11 known
compounds. Reported herein are the isolation, structure deter-
mination, and biological activity of these isolates.2. Results and discussion
Compound 1 showed IR absorptions due to hydroxyl (3216 cm1),
carboxyl (1734 cm1 and 1658 cm1), and aromatic ring
(1616 cm1 and 1516 cm1) functionalities. Its molecular formula
C12H13NO4 was indicated by HR-ESI-MS at m/z 236.0925
[MþH]þ (Calcd. for C12H14NO4 236.0917) and the NMR spectral
data (Table 1). The NMR spectral data of 1 showed that thisFigure 1 The structurcompound consisted of 40-hydroxybenzyl and pyroglutamate
moieties21. This was veriﬁed by the 1H–1H COSY correlations
of H-2/H2-3/H2-4 and HMBC correlations from H-2 to C-1, from
H2-3 to C-1 and C-5, and from H2-4 to C-5. In particular, the
HMBC correlations from H2-70 to C-2 and C-5 located the 40-
hydroxybenzyl unit at the N atom of the pyroglutamate moiety.
Thus, the planar structure of 1 was determined as N-(40-hydro-
xybenzyl)pyroglutamate. The absolute conﬁguration of 1 was
assigned by synthesis of enantiomers (þ)-(S)- and ( )-(R)-[N-
(40-hydroxybenzyl)]pyroglutamates, starting with L- and D-gluta-
mic acids, respectively. The CD and speciﬁc rotation data of 1
were consistent with those of (þ)-(S)-[N-(40-hydroxybenzyl)]
pyroglutamate. Therefore, the structure of compound 1 was
determined as shown.
Compound 2 has the molecular formula C14H17NO4 as
indicated by the HR-ESI-MS and NMR data (Table 1 and
Section 4). Comparison of the NMR data of 2 and 1 indicated
the presence of an ethoxy group [δH 4.11 (q, 2H, J¼7.2 Hz) and
δH 1.21 (t, 3H, J¼7.2 Hz); δC 61.7 and δC 14.4] and shielded
shifts of C-1 and C-5 by ΔδC 0.7 ppm and 0.6 ppm,
respectively in 2. This revealed that 2 is the ethyl ester of 1,
which was conﬁrmed by the HMBC correlation from OCH2CH3
to C-1 in the HMBC spectrum of 2. The CD and speciﬁc
rotation data of 2 were similar with those of 1, indicating that
the two compounds have the same conﬁguration, which was
further conﬁrmed by synthesis of the enantiomers, ethyl
(þ)-(S)- and ( )-(R)-[N-(40-hydroxybenzyl)]pyroglutamates.
The CD and speciﬁc rotation data of 2 were in agreement with
those of the former enantiomer. Thus, the structure of com-
pound 2 was determined as shown.
The molecular formula C21H23NO5 of compound 3 was
determined from its HR-ESI-MS and NMR data (Table 1 and
Section 4). Comparison of the NMR data of 3 and 2 suggests that
3 is an analog of 2 with an additional 4″-hydroxybenzyl unit
substituted at C-30. This was conﬁrmed by the 1H-1H COSY
correlations of H-2/H2-3/H2-4 and HMBC correlations of H-2/C-1
and C-5; H2-3/C-1 and C-5; H2-4/C-5; OCH2CH3/C-1; 400-OH/
C-30 0, C-40 0, and C-50 0; H-70 0/C-20, C-30, C-40, C-10 0, C-20 0, and
C-60 0; 40-OH/C-30, C-40, and C-50; H-70/C-10, C-2, C-20, C-5, and
C-60. Similarity of the CD and speciﬁc rotation data between 3 and
2 suggested the same 2(S) conﬁguration for the two compounds.
Thus, compound 3 was determined as ethyl (þ)-(S)-{N-[40-
hydroxy-30-(4″-hydroxybenzyl)benzyl]}pyroglutamate.es of compounds 18.
Table 1 1H NMR and 13C NMR spectral data (δ) for compounds 17.a.
No. 1 2 3b 4 5 6 7
δH δC δH δC δH δC δH δC δH δC δH δC δH δC
1 173.4 172.7 172.6 173.0 172.5 176.7 174.3
2 4.01 dd
(9.0,
3.6)
58.9 3.97 dd
(9.0, 3.0)
59.4 3.90 dd
(8.4, 3.6)
59.2 4.19 m 70.4 4.16 m 70.4 4.26 brs 72.1 4.11 m 68.6
3a 2.33 m 23.4 2.28 m 23.4 2.22 m 23.3 2.67 dd
(13.5, 5.5)
34.5 2.67 dd
(14.0, 5.5)
34.5 2.83 brd
(13.8)
36.3 1.82 m 33.7
3b 2.08 m 2.01 m 1.99 m 2.58 dd
(13.5, 6.5)
2.57 dd
(14.0, 6.0)
2.69 dd
(13.8, 6.6)
1.76 m
4a 2.43 m 30.2 2.38 m 30.3 2.37 m 30.5 2.41 m 26.3
4b 2.36 m 2.30 m 2.26 m
5 175.5 174.9 174.9
10 127.9 128.1 127.9 128.3 128.3 130.4 128.5
20 7.08 d
(8.4)
130.5 7.05 d
(8.4)
130.5 6.88 d
(2.4)
131.3 7.09 d (8.0) 130.0 7.09 d (8.5) 130.0 7.15 d (8.4) 131.3 7.08 d
(8.5)
129.9
30 6.79 d
(8.4)
116.1 6.78 d
(8.4)
116.1 129.4 6.69 d (8.0) 115.1 6.69 d (8.5) 115.1 6.71 d (8.4) 116.1 6.68 d
(8.5)
115.1
40 157.7 157.7 155.3 156.2 156.2 157.5 156.2
50 6.79 d
(8.4)
116.1 6.78 d
(8.4)
116.1 6.79 d
(8.4)
116.0 6.69 d (8.0) 115.1 6.69 d (8.5) 115.1 7.15 d (8.4) 116.1 6.68 d
(8.5)
115.1
60 7.08 d
(8.4)
130.5 7.05 d
(8.4)
130.5 6.87 dd
(8.4, 2.4)
128.0 7.09 d (8.0) 130.0 7.09 d (8.5) 130.0 6.71 d (8.4) 131.3 7.08 d
(8.5)
129.9
70a 4.94 d
(15.0)
45.2 4.82 d
(15.0)
45.3 4.80 d
(14.4)
45.3 3.67 s 35.3 3.67 s 35.3 3.73 s 37.1 3.60 s 34.5
70b 3.85 d
(15.0)
3.87 d
(15.0)
3.79 d
(14.4)
OCH3 3.63 s 51.6 3.62 s 51.5
OCH2CH3 4.11 q
(7.2)
61.7 4.08 q
(7.2)
61.7 4.09 q
(7.0)
60.2
OCH2CH3 1.21 t
(7.2)
14.4 1.18 t
(7.2)
14.4 1.19 t
(7.0)
14.1
2-OH 5.75 d
(6.0)
5.71 d
(6.0)
5.49 d
(6.0)
40-OH 8.31 s 8.44 s 9.32 s 9.33 s 9.34 s
aNMR data (δ) were measured in Me2CO-d6 for 13 at 600 MHz for 1H and at 150 MHz for 13C, in DMSO-d6 for 4, 5, and 7 at 500 MHz for 1H
and at 125 MHz for 13C and in MeOH-d4 for 6 at 600 MHz for
1H and at 150 MHz for 13C. Proton coupling constants (J) in Hz are given in
parentheses. The assignments were based on DEPT, 1H-1H COSY, HSQC, and HMBC experiments.
bData for 4″-hydroxybenzyl in 3: δH 8.16 (s, 1H, OH-4″), 7.05 (d, 2H, J¼8.4 Hz, H-2″/6″), 6.71 (d, 2H, J¼8.4 Hz, H-3″/5″), 3.82 (s, 2H, H2-7″);
δC 132.7 (C-1″), 130.6 (C-2″/6″), 115.8 (C-3″/5″), 156.4 (C-4″), 35.4 (C-7″).
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by the HR-ESI-MS and NMR data (Table 1 and Section 4).
Comparing the NMR data between 4 and the synthetic methyl
S-(40-hydroxybenzyl)-L-cysteinate, the chemical shift of C-2
(δC 70.4) and the presence of an exchangeable hydroxy proton [δ
5.75 (d, 1H, J¼6.0 Hz)] in the NMR spectra of 4 in DMSO-d6
demonstrated the replacement of the amino group in the synthetic
compound by a hydroxyl group in 4. This was proved by the two-
and three-bond correlations from H2-3 to C-70; from H2-70 to C-10, C-
20 (C-60), and C-3; from OH to C-1, C-2, and C-3; and from OCH3 to
C-1 in the HMBC spectrum of 4. The absolute conﬁguration at C-2 in
4 was determined by the modiﬁed Mosher’s method22. Esteriﬁcation
of 4 with ( )-(R)- and (þ)-(S)-α-methoxyphenylacetic acid (MPA)
afforded the corresponding derivatives, 4-bis-(R)-MPA and 4-bis-(S)-
MPA. Since the MPA moiety at C-40 of the benzyl unit is away from
the chiral center (C-2) in the bis-MPA esters, the chemical shift
change of protons around C-2 is mainly induced by the MPA moiety
at C-2. From the MPA determination rule based on the ΔδRS values
(Fig. 2), the conﬁguration of 4 was assigned as 2S. Therefore, the
structure of compound 4 was determined as shown.Compound 5 (C12H16O4S) is an analog of 4, as indicated by its
spectroscopic data (Table 1 and Section 4). Comparison of the
NMR data of 5 and 4 indicated that the methoxyl group in 4 was
substituted by an ethoxyl group [δH 4.09 (q, 2H, J¼7.0 Hz,
OCH2CH3) and δH 1.19 (t, 3H, J¼7.0 Hz, OCH2CH3); and δC
60.2 and δC 14.1] in 5. The HMBC correlations from OCH2CH3 to
C-1 conﬁrmed the ester linkage of the ethoxyl group. The
S-conﬁguration of 5 was veriﬁed by Mosher’s method (Fig. 2).
Thus, compound 5 was determined as ethyl (þ)-(S)-2-hydroxy-3-
[(40-hydroxybenzyl)thio]propanoate.
The spectroscopic data of compound 6 indicated that it is the
acid form of 4 and 5. The NMR data of 6 demonstrated a
deshielded shift of the C-1 resonance (ΔδC4þ3.0 ppm), as
compared with that of 4 or 5, in addition to the absence of the
methoxyl or ethoxyl group. An ethanol solution of 6 was treated
with thionyl chloride (SOCl2) to yield 5. Therefore, compound 6
was determined as (þ)-(S)-2-hydroxy-3-[(40-hydroxybenzyl)thio]
-propanoic acid.
The spectroscopic data of compound 7 indicated that it is
an isomer of 5. Comparing the NMR data of these two compounds
Figure 2 ΔδRS values (δRδS, black data in ppm) for bis-MPA esters of compounds 4, 5, and 7.
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xypropanoate moiety as in 5, compound 7 contained a methyl
2-hydroxybutyrate moiety. The 1H-1H COSY correlations of
H-2/H2-3/H2-4 and HMBC correlations of H-2/C-1, C-3, and C-
4; H2-3/C-1, C-2, and C-4; H2-4/C-2 and C-3, and OCH3/C-1,
along with their chemical shifts, conﬁrmed the presence of the
methyl 2-hydroxybutyrate moiety with the sulfur atom substituted
at C-4 in 7. In addition, the HMBC correlations from H2-4 to C-70
and from H2-70 to C-4 veriﬁed the 40-hydroxylbenzyl unit located
at the sulfur atom. The 2R conﬁguration of 7 was determined by
using the same protocol as described for 4 and 5 (Fig. 2).
Therefore, compound 7 was determined as methyl ( )-(R)-2-
hydroxy-4-[(40-hydroxybenzyl)thio]butyrate.
The acid/ester pair of 1/2 and the ethyl ester 3 are considered as
natural products because HPLC-ESI-MS analysis using the ion
extraction method demonstrated their occurrence in the crude extract
or an CH3CN-eluted fraction without contacting with EtOH. In
addition, methylation or ethylation of the acids and hydrolysis of the
esters were unlikely to occur in the isolation procedure because
reﬂuxing the EtOH solution of L-[N-(40-hydroxybenzyl)]glutamic acid
only produced 1, whereas 2 was obtained by subsequent addition of
thionyl chloride (SOCl2) in the solution. However, the esters 4, 5,
and/or 7 may be artifacts because 6 was esteriﬁed by keeping the
MeOH solution at room temperature for a month, producing the ester
with the spectroscopic features identical to that of 4 (Figs. S125–127
in Supporting information).
The known compounds were identiﬁed by comparing their spectro-
scopic data with the reported data as cyclo[glycine-L-S-(40 0-hydro-
xybenzyl)cysteine]23, 2-[4-(β-D-glucopyranosyl)benzyl]citrate24, 1-
ethyl citrate25, 6-ethyl citrate26, parishin E, 4-(hydroxymethyl)-5-
nitrobenzene-1,2-diol (8)27, ( )-(6R)-6,7-dihydroxy-3,7-dimethyl-
(2E)-octenoic acid28, bis(4-hydroxybenzyl)sulﬁde29, ethyl (þ)-(2S)-2-
hydroxy-3-(4-hydroxyphenyl)propanoate30, 1-(40-hydroxyphenyl)pro-
pan-1,2-dione31, and ( )-4-β-D-glucopyranosyl-(1-6)-β-D-glucopyr-
anosyloxybenzyl alcohol32.
In the in vitro bioassays, compound 8 showed activity against
Fe2þ-cysteine induced rat liver microsomal lipid peroxidation, with
IC50 value of 9.99 106 mol/L (the positive control, glutathione,
gave IC50 20.21 106 mol/L). All other compounds isolated in
this experiment were inactive at the same concentration. In addition,
these compounds were also evaluated for the scavenging activity of
1,1-diphenyl-2-picrylhydrazyl (DPPH) radical and their inhibitory
activity against Fe2þ/cysteine-induced liver microsomal lipid per-
oxidation, several human cancer cell lines, HIV-1 replication, and
all of them were inactive at a concentration of 105 mol/L.3. Conclusion
Seven new 4-hydroxybenzyl-substituted amino acid derivatives
(17), together with 11 known compounds, were isolated from an
aqueous extract of the rhizomes of G. elata. Blume. Compounds13 are pyroglutamate derivatives containing 4-hydroxybenzyl units
at the N atom and 47 are the ﬁrst examples of natural products with
the 4-hydroxybenzyl unit linked via a thioether bond to 2-hydroxy-3-
mercaptopropanoic acid (46) and 2-hydroxy-4-mercaptobutanoic
acid (7), which would be biogenetically derived from cysteine and
homocysteine, respectively. The enantiomers of compounds 1 and 2
were synthesized, and the absolute conﬁgurations of 4, 5 and 7 were
assigned using Mosher’s method. These results, combined with our
previous studies18, provide an important clue for further studies of
chemical transformation, structural modiﬁcation, and biosynthesis of
the diverse 4-hydroxybenzyl-substituted amino acid derivatives from
the rhizome of G. elata, as well as for evaluations on other
pharmacological models though the new compounds were inactive
in the assays carried out in this study.4. Experimental
4.1. General experimental procedures
Optical rotations were measured using a Rudolph Research
Autopol III polarimeter. UV spectra were measured on a Cary
300 spectrometer. CD spectra were measured on a JASCO J-810
spectropolarimeter. IR spectra were recorded on a Nicolet 5700
FT-IR microscope spectrometer (FT-IR microscope transmission)
by microscope transmission method. 1D- and 2D-NMR spectra
were obtained on INOVA 400 MHz, 500 MHz, or SYS 600 MHz
spectrometers (Varian), with solvent peaks serving as references
(unless otherwise noted). ESI-MS data were measured with a
Q-Trap LC/MS/MS (Turbo Ionspray source) spectrometer. HR-
ESI-MS data were, in turn, measured on an AccuTOF-CS JMS-
T100CS spectrometer (JEOL), and HR-EI-MS data were measured
using a Micromass Autospec-Ultima ETOF spectrometer. Column
chromatography was performed with silica gel (200–300 mesh,
Qingdao Marine Chemical Inc., Qingdao, China) and Sephadex
LH-20 (Pharmacia Biotech AB, Uppsala, Sweden), Toyopearl
HW-40C and HW-40F (Tosoh Bioscience LLC, Tokyo, Japan),
and MCI gel (CHP20P) (Mitsubishi Chemical Inc., Tokyo, Japan).
HPLC separation was performed on an instrument with a Waters
600 controller, a Waters 600 pump, and a Waters 2487 dual λ
absorbance detector (detecting wavelength: 230 nm) on a Grace
(250 mm 10 mm, i.d.) semi-preparative column packed with
C18 (5 μm), and an YMC-Pack (250 mm 10 mm, i.d.) column
packed with Ph (5 μm). Glass precoated silica gel GF254 plates
were used for TLC. Spots were visualized under UV light or by
spraying with 5% H2SO4 in EtOH, followed by heating.4.2. Plant material
The rhizomes of G. elata were collected at the plantation ﬁeld
of Xiaocao Ba, Yunnan province, China, in December 2009.
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Materia Medica, Beijing 100050, China). A voucher specimen
(No. ID-S-2384) was deposited at the herbarium of the Department
of Medicinal Plants, Institute of Materia Medica, Beijing
100050, China.
4.3. Extraction and isolation
The steamed and air-dried G. elata rhizomes (50 kg) were
pulverized and ultrasonicated with H2O (150 L 3 1 h). The
aqueous extracts were combined and evaporated under reduced
pressure to yield a concentrated solution (50 L), which was loaded
on a macroporous adsorbent resin (HPD-100, 30 kg) column
(20 cm 200 cm), and eluted successively with H2O (50 L),
30% EtOH (150 L), 50% EtOH (120 L) and 95% EtOH (80 L)
to yield four corresponding fractions AD. After removing the
solvent under reduced pressure, fraction C (1.9 kg) was chromato-
graphed over MCI gel (CHP 20P, 10 L), with successive elution
using H2O (30 L), 30% EtOH (70 L), 50% EtOH (70 L), 95%
EtOH (30 L) and Me2CO (20 L), to afford fractions C1C5.
Fraction C3 (237 g) was subjected to column chromatography
(CC) over silica gel, eluting with a gradient of increasing MeOH
concentration (0100%) in EtOAc followed by 30% EtOH, to
yield fractions C3-1–C3-5 based on TLC analysis. Fraction C3-1
(27.3 g) was separated by silica gel CC (petroleum ether-ethyl
acetate, 50:1 v/v to 1:1 v/v) to give C3-1-1C3-1-6. Separation of
C3-1-1 (780 mg) by RP ﬂash CC (10%70% MeOH in H2O)
afforded C3-1-1-1–C3-1-1-8. Puriﬁcation of C3-1-1-1 (120 mg) by
HPLC (C18 column, 2.0 mL/min, 45% MeOH in H2O) gave 2
(34 mg, tR¼28.7 min), and C3-1-1-4 (42.5 mg) by HPLC (45%
MeCN in H2O) gave 5 (22 mg, tR¼18.2 min, C18 column,
2.0 mL/min). Separation of C3-1-3 (900 mg) by silica gel CC
(CHCl3–MeOH, 15:1 v/v) yielded subfractions C3-1-3-1C3-1-3-
7, of which C3-1-3-7 (234 mg) was further fractioned by CC over
Sephadex LH-20 (MeOH-H2O, 1:1 v/v) to obtain C3-1-3-7-1 and
C3-1-3-7-2. Fraction C3-1-3-7-1 (27 mg) was puriﬁed by HPLC
(Ph column, 52% MeOH in H2O, 2.0 mL/min) to obtain 3 (2.7 mg,
tR¼34.5 min). Fraction C3-1-4 (1.25 g) was further separated by
silica gel CC (CHCl3–MeOH, 10:1 v/v to 1:1 v/v) to afford C3-1-4-
1–C3-1-4-4, of which C3-1-4-4 (640 mg) was fractionated by CC
over Sephadex LH-20 (MeOH–H2O, 1:1 v/v) to yield C3-1-4-4-1–
C3-1-4-4-7. Separation of C3-1-4-4-3 (74 mg) by CC over HW-
40F (MeOH) gave C3-1-4-4-3-1 and C3-1-4-4-3-2, of which C3-1-
4-4-3-2 (37 mg) was puriﬁed by RP HPLC (Ph column, 20%
MeOH in H2O containing 0.1% TFA, 1.5 mL/min) to yield 1
(19 mg, tR¼14.3 min). Fraction C3-1-4-4-6 (46 mg) was chroma-
tographed over HW-40F (MeOH), followed by RP HPLC (C18
column, 25% MeOH in H2O containing 0.1% TFA, 2.0 mL/min),
to afford 6 (9 mg, tR¼45.3 min). Fraction C3-2 (120 g) was
separated by silica gel CC (ethyl acetate-MeOH, 100:1 v/v to 1:1
v/v) to give C3-2-1C3-2-7. Separation of C3-2-5 (47 g) by CC
over Sephadex LH-20 (30% MeOH in H2O) afforded subfractions
C3-2-5-1–C3-2-5-21, of which C3-2-5-18 (240 mg) was puriﬁed
by RP HPLC (C18 column, 55% MeOH in H2O, 2.0 mL/min) to
give 4 (19.7 mg, tR¼16.5 min), and C3-2-5-6 by reduced pressure
HPLC (C18 column, 50% MeOH in H2O, 2.0 mL/min) gave 7
(11.1 mg, tR¼21.2 min).
4.3.1. (þ)-(S)-[N-(40-Hydroxybenzyl)]pyroglutamate (1)
Colorless gum; α½ 20D þ43.2 (c 0.11, MeOH); UV (MeOH) λmax
(logε): 203 (3.16), 226 (3.05), 277 (2.20) nm; CD (MeOH) 224(Δε þ16.3) nm; IR (Nujol): νmax 3216, 3020, 2952, 2719, 1735,
1659, 1616, 1516, 1452, 1420, 1359, 1232, 1174, 1108, 961, 851,
837 cm1; 1H NMR (CD3OD, 600 MHz) data, see Table 1;
13C
NMR (CD3OD, 150 MHz) data, see Table 1; (þ)-ESI-MS m/z 236
[MþH]þ, 258 [MþNa]þ, 274 [MþK]þ, 471 [2MþH]þ, 493
[2MþNa]þ; (þ)-HR-ESI-MS m/z 236.0925 [MþH]þ (Calcd. for
C12H14NO4, 236.0917).
4.3.2. Ethyl (þ)-(S)-[N-(40-hydroxybenzyl)]pyroglutamate (2)
Colorless gum; α½ 20D þ40.2 (c 0.09, MeOH); UV (MeOH) λmax
(logε): 203 (3.36), 226 (3.22), 277 (2.84) nm; CD (MeOH) 224
(Δε þ7.8) nm; IR (Nujol): νmax 3241, 2982, 2935, 1740, 1669,
1615, 1597, 1517, 1451, 1419, 1367, 1269, 1230, 1203, 1107,
1031, 959, 849, 838 cm1; 1H NMR (DMSO-d6, 600 MHz) data,
see Table 1; 13C NMR (DMSO-d6, 150 MHz) data, see Table 1;
(þ)-ESI-MS m/z 264 [MþH]þ, 286 [MþNa]þ, 527 [2MþH]þ,
549 [2MþNa]þ; (þ)-HR-ESI-MS m/z 264.1235 [MþH]þ (Calcd.
for C14H18NO4, 264.1230), 286.1052 [MþNa]þ (Calcd. for
C14H17NO4Na, 286.1050).
4.3.3. Ethyl (þ)-(S)-{N-[40-hydroxy-30-(40 0-hydroxybenzyl)benzyl]}
pyroglutamate (3)
Colorless gum; α½ 20D þ3.1 (c 0.19, MeOH); UV (MeOH) λmax
(logε): 204 (3.39), 227 (2.82), 279 (2.16) nm; CD (MeOH) 222
(Δε þ1.7) nm; IR (Nujol): νmax 3334, 3017, 2981, 2930, 1739,
1668, 1612, 1513, 1444, 1368, 1265, 1209, 1111, 1017, 963, 913,
827 cm1; 1H NMR (Me2CO-d6, 600 MHz) data, see Table 1;
13C
NMR (Me2CO-d6, 150 MHz) data, see Table 1; (þ)-ESI-MS m/z
370 [MþH]þ, 392 [MþNa]þ, 408 [MþK]þ; (þ)-HR-ESI-MS m/z
370.1661 [MþH]þ (Calcd. for C21H24NO5, 370.1649), 392.1487
[MþNa]þ (Calcd. for C21H23NO5Na, 392.1468).
4.3.4. Methyl (þ)-(S)-2-hydroxy-3-[(40-hydroxybenzyl)thio]
propanoate (4)
White amorphous powder; α½ 20D þ68.7 (c 0.02, MeOH); UV
(MeOH) λmax (logε): 226 (4.32), 279 (2.73) nm; IR (Nujol): νmax
3366, 3021, 2955, 2924, 1893, 1738, 1677, 1612, 1514, 1443,
1225, 1143, 1098, 1012, 970, 837 cm1; 1H NMR (DMSO-d6,
500 MHz) data, see Table 1; 13C NMR (DMSO-d6, 125 MHz)
data, see Table 1; (þ)-HR-ESI-MS m/z 265.0508 [MþNa]þ
(Calcd. for C11H14O4SNa, 265.0505).
4.3.5. Ethyl (þ)-(S)-2-hydroxy-3-[(40-hydroxybenzyl)thio]prop-
anoate (5)
White powder; α½ 20D þ34.2 (c 0.04, MeOH); UV (MeOH) λmax
(logε): 227 (4.28), 279 (2.83) nm; IR (Nujol): νmax 3372, 2983,
2927, 1890, 1733, 1679, 1612, 1596, 1514, 1446, 1370, 1224,
1097, 1024, 837 cm1; 1H NMR (DMSO-d6, 500 MHz) data, see
Table 1; 13C NMR (DMSO-d6, 125 MHz) data, see Table 1;
(þ)-HR-ESI-MS m/z 257.0837 [MþH]þ (Calcd. for C12H17O4S,
257.0842), 279.0659 [MþNa]þ (Calcd for C12H16O4SNa,
279.0662).
4.3.6. (þ)-(S)-2-Hydroxy-3-[(40-hydroxybenzyl)thio]propanoate (6)
Colorless gum; α½ 20D þ8.51 (c 0.80, MeOH); UV (MeOH) λmax
(logε): 204 (3.43), 227 (3.31), 280 (2.49) nm; IR (Nujol): νmax 3290,
3020, 2921, 1894, 1729, 1612, 1597, 1514, 1445, 1368, 1235, 1097,
1044, 1022, 980, 835 cm1; 1H NMR (MeOH-d4, 600 MHz) data,
see Table 1; 13C NMR (MeOH-d4, 150 MHz) data, see Table 1;
( )-ESI-MS m/z 227 [M–H], 455 [2M–H]; (þ)-HR-ESI-MS m/z
Substituted amino acid derivatives from Gastrodia elata 355251.0349 [MþNa]þ (Calcd. for C10H12O4SNa, 251.0349), 267.0080
[MþK]þ (Calcd. for C10H12O4SK, 267.0088).
4.3.7. ( )-(R)-2-Hydroxy-4-[(40-hydroxybenzyl)thio]butyrate (7)
White powder; α½ 20D 61.7 (c 0.01, MeOH); UV (MeOH) λmax
(logε): 222 (4.14), 278 (2.77) nm; IR (Nujol): νmax 3352, 2956,
2919, 1891, 1733, 1680, 1613, 1597, 1514, 1443, 1364, 1305,
1234, 1206, 1142, 1097, 1024, 925, 838, 802 cm1; 1H NMR
(DMSO-d6, 500 MHz) data, see Table 1;
13C NMR (DMSO-d6,
125 MHz) data, see Table 1; (þ)-HR-ESI-MS m/z 279.0662
[MþNa]þ (Calcd. for C12H16O4SNa, 279.0662).
4.4. Synthesis of 1 and 2
To a solution of L- or D-glutamic acid (2 g) in MeOH (30 mL),
4-hydroxybenzaldehyde (3 g) and anhydrous Na2CO3 (3 g) were
added. The mixture was stirred at r.t. for 4 h, cooled to 0 1C, and
NaBH4 (1 g) was slowly added by keeping the temperature at
05 1C. The mixture was stirred at r.t. for 40 min, and acidiﬁed
with 2 mol/L HCl to pH 3 at 05 1C to produce precipitate, which
was collected by ﬁltration, washed with cold water, and dried to
afford L- or D-[N-(4-hydroxybenzyl)]glutamic acid (1.4 g)33.
A suspension of L- or D-[N-(4-hydroxybenzyl)]glutamic acid
(200 mg) in ethanol (15 mL) was reﬂuxed for 5 h. The resulting
solution was ﬁltrated, followed by evaporation of the ﬁltrate, to
afford (þ)-(S)-[N-(4-hydroxybenzyl)]pyroglutamate (126 mg)
from L-[N-(4-hydroxybenzyl)]glutamic acid or ( )-(R)-[N-(4-
hydroxybenzyl)]pyroglutamate (138 mg) from D-[N-(4-hydroxy-
benzyl)]glutamic acid. (þ)-(S)-[N-(4-Hydroxybenzyl)]pyrogluta-
mate: colorless gum; α½ 20D þ49.8 (c 1.6, MeOH); CD (MeOH)
223 (Δε þ11.9) nm; 1H NMR (400 MHz, CD3COCD3): δ 7.06 (d,
2H, J¼7.6 Hz, H-20/60), 6.78 (d, 2H, J¼7.6 Hz, H-30/50), 4.93 (d,
1H, J¼14.8 Hz, H-70a), 3.97 (d, 1H, J¼8.4 Hz, H-2), 3.82 (d, 1H,
J¼14.8Hz, H-70b), 2.32–2.41 (m, 3H, H-3a/4a/4b), 2.08 (m, 1H,
H-3b); 13C NMR (100 MHz, CD3COCD3): δ 175.6 (C-5), 173.4
(C-1), 157.7 (C-40), 130.5 (C-20/60), 128.0 (C-10), 116.2 (C-30/50),
59.0 (C-2), 45.3 (C-70), 30.2 (C-4), 23.5 (C-5); (þ)-ESI-MS m/z
236 [MþH]þ, 258 [MþNa]þ. ( )-(R)-[N-(4-Hydroxybenzyl)]
pyroglutamate: colorless gum; α½ 20D 46.5 (c 1.1, MeOH); CD
(MeOH) 223 (Δε 31.3) nm; 1H NMR (400 MHz, CD3COCD3):
δ 7.07 (d, 2H, J¼8.0 Hz, H-20/60), 6.78 (d, 2H, J¼8.0 Hz, H-30/
50), 4.94 (d, 1H, J¼14.8 Hz, H-70a), 4.00 (d, 1H, J¼8.0 Hz, H-2),
3.84 (d, 1H, J¼14.8 Hz, H-70b), 2.30–2.45 (m, 3H, H-3a/4a/4b),
2.07 (m, 1H, H-3b); 13C NMR (100 MHz, CD3COCD3): δ 175.9
(C-5), 173.4 (C-1), 157.8 (C-40), 130.6 (C-20/60), 127.8 (C-10),
116.2 (C-30/50), 59.0 (C-2), 45.3 (C-70), 30.4 (C-4), 23.5 (C-5);
(þ)-ESI-MS m/z 236 [MþH]þ, 258 [MþNa]þ. The NMR data of
the synthetic compounds (Figs. S1618 and S2123 in
Supporting information) were consistent with those of 1.
To the suspension of L-[N-(4-hydroxybenzyl)]glutamic acid
(200 mg) in ethanol (15 mL), SOCl2 (5 mL) was slowly added
at 0 1C, and stirred for 1 h. Then, the mixture was reﬂuxed for
5 h. The resulting solution was ﬁltrated, followed by evaporation
of the ﬁltrate, to afford ethyl (þ)-(S)-[N-(4-hydroxybenzyl)]pyr-
oglutamate (167 mg). By changing the starting material to
D-[N-(4-hydroxybenzyl)]glutamic acid, ethyl ( )-(R)-[N-(4-
hydroxy benzyl)]pyroglutamate (124 mg) was obtained. Ethyl
(þ)-(S)-[N-(4-hydroxybenzyl)]pyroglutamate: colorless gum;
α½ 20D þ47.5 (c 1.7, MeOH); CD (MeOH) 222 (Δε þ10.0) nm;
1H NMR (400 MHz, CD3COCD3): δ 8.31 (s, 1H, OH-40), 7.05 (d,
2H, J¼7.6 Hz, H-20/60), 6.78 (d, 2H, J¼7.6 Hz, H-30/50), 4.82 (d,1H, J¼14.8 Hz, H-70a), 4.11 (q, 2H, J¼7.2 Hz, OCH2CH3), 3.97
(d, 1H, J¼6.0 Hz, H-2), 3.87 (d, 1H, J¼14.8 Hz, H-70b), 2.39 (m,
1H, H-4a), 2.27 (m, 2H, H-3a/4b), 2.00 (m, 1H, H-3b), 1.21 (t, 3H,
J¼7.2 Hz, OCH2CH3); 13C NMR (150 MHz, CD3COCD3): δ
174.9 (C-5), 172.7 (C-1), 157.7 (C-40), 130.5 (C-20/60), 128.1 (C-
10), 116.1 (C-30/50), 61.7 (OCH2CH3), 59.3 (C-2), 45.2 (C-70), 30.2
(C-4), 23.4 (C-5), 14.4 (OCH2CH3); (þ)-ESI-MS m/z 263
[MþH]þ, 286 [MþNa]þ, 527 [2MþH]þ, 549 [2MþNa]þ. Ethyl
( )-(R)-[N-(4-hydroxybenzyl)]pyroglutamate: colorless gum;
α½ 20D 45.7 (1.5, MeOH); CD (MeOH) 222 (Δε 17.0) nm; 1H
NMR (600 MHz, CD3COCD3): δ 8.45 (s, 1H, OH-40), 7.07 (d, 2H,
J¼8.0 Hz, H-20/60), 6.80 (d, 2H, J¼8.0 Hz, H-30/50), 4.85 (d, 1H,
J¼14.4 Hz, H-70a), 4.14 (q, 2H, J¼7.2 Hz, OCH2CH3), 4.00 (dd,
1H, J¼8.4, 2.4 Hz, H-2), 3.91 (d, 1H, J¼14.4 Hz, H-70b), 2.43
(m, 1H, H-4a), 2.32 (m, 1H, H-4b), 3.20 (m, 1H, H-3a), 2.05 (m,
1H, H-3b), 1.23 (t, 3H, J¼7.2 Hz, OCH2CH3); 13C NMR
(150 MHz, CD3COCD3): δ 174.8 (C-5), 172.6 (C-1), 157.6 (C-
40), 130.4 (C-20/60), 128.0 (C-10), 116.0 (C-30/50), 61.6
(OCH2CH3), 59.3 (C-2), 45.1 (C-70), 30.3 (C-4), 23.3 (C-5),
14.3 (OCH2CH3); (þ)-ESI-MS m/z 263 [MþH]þ, 286 [MþNa]þ,
527 [2MþH]þ, 549 [2MþNa]þ. The NMR data of the synthetic
compounds (Figs. S3941 and S4446 in Supporting
information) were identical with those of 2.
4.5. Synthesis of bis-(R)-MPA and bis-(S)-MPA esters of 4, 5, and 7
R- or S-MPA (10 mg) was added to solutions of 4, 5, or 7
(0.5 mg), EDCI (10 mg), and DMAP (5 mg) in freshly
distilled methylene chloride (3 mL), and kept at r.t. overnight. The
reaction mixtures were separated by preparative TLC (mobile phase:
petroleum ether/Me2CO= 2:1 v/v) to yield 4-bis-(R)-MPA or 4-bis-
(S)-MPA from 4, 5-bis-(R)-MPA or 5-bis-(S)-MPA from 5, and 7-bis-
(R)-MPA or 7-bis-(S)-MPA from 7. 4-Bis-(R)-MPA: 1H NMR
(400 MHz, CDCl3): δ 7.23 (d, 2H, J¼8.4 Hz, H-20/60), 6.92 (d,
2H, J¼8.4 Hz, H-30/50), 5.28 (dd, 1H, J¼7.6, 4.0 Hz, H-2), 3.69 (s,
2H, H2-70), 3.61 (s, 3H, OCH3), 2.84 (dd, 1H, J¼14.4, 4.0 Hz, H-
3a), 2.76 (dd, 1H, J¼14.4, 7.6 Hz, H-3b). 4-Bis-(S)-MPA: 1H NMR
(400 MHz, CDCl3): δ 7.10 (d, 2H, J¼8.8 Hz, H-20/60), 6.88 (d, 2H,
J¼8.8 Hz, H-30/50), 5.28 (dd, 1H, J¼6.8, 4.8 Hz, H-2), 3.71 (s, 3H,
–OCH3), 3.50 (s, 2H, H2-70), 2.73 (m, 2H, H2-3). 5-Bis-(R)-MPA:
1H
NMR (400 MHz, CDCl3): δ 7.23 (d, 2H, J¼8.8 Hz, H-20/60), 6.92
(d, 2H, J¼8.8 Hz, H-30/50), 5.26 (dd, 1H, J¼7.2, 3.6 Hz, H-2), 4.08
(q, 2H, J¼7.2 Hz, OCH2CH3), 3.70 (s, 2H, H2-70), 2.84 (dd, 1H,
J¼14.8, 3.6 Hz, H-3a), 2.77 (dd, 1H, J¼14.8, 7.2 Hz, H-3b), 1.12 (t,
3H, J¼7.2 Hz, OCH2CH3). 5-Bis-(S)-MPA: 1H NMR (400 MHz,
CDCl3): δ 7.11 (d, 2H, J¼8.4 Hz, H-20/60), 6.88 (d, 2H, J¼8.4 Hz,
H-30/50), 5.25 (dd, 1H, J¼6.8, 5.2 Hz, H-2), 4.17 (q, 2H, J¼7.2 Hz,
OCH2CH3), 3.53 (d, 1H, J¼13.2, H-7a0), 3.50 (d, 1H, J¼13.2, H-
7b0), 2.74 (m, 2H, H2-3), 1.21 (t, 3H, J¼7.2Hz, OCH2CH3). 6-Bis-
(R)-MPA: 1H NMR (400 MHz, CDCl3): δ 7.23 (d, 2H, J¼8.4 Hz,
H-20/60), 6.93 (d, 2H, J¼8.4 Hz, H-30/50), 5.18 (dd, 1H, J¼6.4,
6.0 Hz, H-2), 3.60 (s, 2H, H2-7’), 3.56 (s, 3H, OCH3), 2.36 (m, 2H,
H2-4), 2.06 (m, 2H, H2-3). 6-Bis-(S)-MPA:
1H NMR (400 MHz,
CDCl3): δ 7.20 (d, 2H, J¼8.4 Hz, H-20/60), 6.94 (d, 2H, J¼8.4 Hz,
H-30/50), 5.16 (dd, 1H, J¼7.6, 4.8 Hz, H-2), 3.71 (s, 3H, OCH3),
3.52 (s, 2H, H2-7’), 2.15 (m, 2H, H2-4), 2.00 (m, 2H, H2-3).
4.6. Synthesis of methyl S-(4-hydroxybenzyl)-L-cysteinate
Methyl L-cysteinate (10 mg) and 4-hydroxybenzylalcohol (13 mg)
were added to 5 mL of 2 mol/L HCl. The mixture was stirred at r.t.
Qinglan Guo et al.356for 20 min, and extracted with EtOAc (5 3 mL). The organic
layer was evaporated under reduced pressure. The residue was
chromatographed over Toyopearl HW-40F, using H2O as the
mobile phase to afford methyl S-(4-hydroxybenzyl)]-L-cysteinate
(14 mg): white amorphous powder, α½ 20D þ37.6 (c 2.43, MeOH);
1H NMR (DMSO-d6, 400 MHz): δ 2.94 (m, 2H, H2-3), 3.70
(s, 2H, H2-70), 3.73 (s, 3H, OCH3), 4.23 (brt, 1H, J¼6.0 Hz, H-2),
6.73 (d, 2H, J¼8.4 Hz, H-30/50), 7.12 (d, 2H, J¼8.4 Hz, H-20/60),
8.85 (s, 3H, OH and NH2).
13C NMR (DMSO-d6, 100 MHz): δ
30.7 (C-3), 35.1 (C-70), 51.8 (OCH3), 52.9 (C-2), 115.3 (C-30/50),
127.5 (C-10), 130.1 (C-20/60), 156.6 (C-40), 168.7 (C-1). (þ)-ESI-
MS m/z 242 [MþH]þ, 242 [MþNa]þ.
4.7. Antioxidant activity assay against Fe2þ/cysteine-induced
liver microsomal lipid peroxidation
See Ref. 34.
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